Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice

Gene Therapy

Volumn 16, Issue 11, 2009, Pages 1373-1379

  Trionfini, P ^a   Tomasoni, S ^a   Galbusera, M ^a   Motto, D ^b   Longaretti, L ^a   Corna, D ^a   Remuzzi, G ^a,c   Benigni, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF IOWA   (United States)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; MUS;

EID: 70449710864     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.98     Document Type: Article

References (24)

1. Remuzzi G, Ruggenenti P, Bertani T. Thrombotic microangiopathies. In: Tisher CC, Brenner BM (eds). Renal Pathology with Clinical and Functional Correlations, 2nd edn, vol. 2. J.B. Lippincott Company: Philadelphia, PA, 1994, pp 1154-1184.
2. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura - then and now. Semin Thromb Hemost 2006; 32: 81-89.
3. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 4223-4234.
4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
5. Donadelli R, Banterla F, Galbusera M, Capoferri C, Bucchioni S, Gastoldi S et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96: 454-464.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
7. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
8. Barbot J, Costa E, Guerra M, Barreirinho MS, Isvarlal P, Robles R et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113: 649-651.
9. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 589-600.
10. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297: 1386-1389.
11. Moake JL. Thrombotic thrombocytopenic purpura: Survival by 'giving a dam'. Trans Am Clin Climatol Assoc 2004; 115: 201-219.
12. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-776.
13. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 1999; 6: 1520-1535.
14. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75 11284-11291.
15. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E et al von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic and hemolytic uremic syndrome. Blood 2002; 100: 778-785.
16. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. Thromb Haemost 1999; 82: 1386-1389.
17. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115 2752-2761.
18. Galbusera M, Remuzzi A, Benigni A, Rossi C, Remuzzi G. A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. Am J Kidney Dis 2000; 36: 695-702.
19. Niiya M, Endo M, Shang D, Zoltick PW, Muvarak NE, Cao W et al. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther 2009; 17 34-41.
20. Laje P, Shang D, Cao W, Niiya M, Endo M, Radu A et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 2009; 113: 2172-2180.
21. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005; 11: 66-79.
22. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007; 7 189-204.
23. Blagbrough IS, Zara C. Animal models for target diseases in gene therapy - using DNA and siRNA delivery strategies. Pharm Res 2009; 26 1-18.
24. Allocca M, Doria M, Petrillo M, Colella P, Garcia-Hoyos M, Gibbs D et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008; 118: 1955-1964.